In this Issue:
Cardioprotection of dexrazoxane in paediatric ALL/NHL
Gemtuzumab ozogamicin in elderly AML
Lenalidomide vs standard therapy in relapsed/ refractory MCL
Ibrutinib + bendamustine and rituximab in CLL/SLL
MRD monitoring in CBFA-AML
Blinatumomab in relapsed/ refractory DLBCL
Impact of BCR-ABL transcript type
HSCT vs drug therapy in newly-diagnosed CML
Clofarabine before HSCT in relapsed/refractory AML
SC vs IV rituximab in CLL
Please login below to download this issue (PDF)